Clinical Trials

21 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06618014 2026-05-15

NeoTOP

51 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03574571 2026-05-14

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

732 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT03598595 2026-05-14

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

31 enrolled

Sarcoma

Osteosarcoma

NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1/2 Active not recruiting

18 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT02495896 2026-04-29

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

GastrointestinalHead & NeckThoracic

61 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Pancreatic Neoplasms

NCT05645380 2026-04-28

NeoTRACT

139 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00076310 2026-04-15

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

50 enrolled 11 charts

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT05616624 2026-04-15

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

31 enrolled

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT04745988 2026-04-09

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

43 enrolled

Stomach Neoplasms

NCT06734130 2026-04-01

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT03360890 2026-03-13

iPRIME

46 enrolled

Salivary Gland Neoplasms, Thyroid Neoplasms

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Breast Neoplasms

NCT04030455 2026-03-09

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

28 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms

NCT00707473 2026-03-05

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

31 enrolled

Sinonasal undifferentiated carcinoma, Paranasal Sinus Neoplasms

NCT04522336 2026-03-05

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

16 enrolled

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

NCT07421141 2026-02-27

Opti-HER2

186 enrolled

Breast Neoplasms

NCT04884282 2026-02-06

COMBI-TED

105 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04340882 2026-01-30

DoceRamPem

30 enrolled

Lung Neoplasms

NCT05500092 2026-01-28

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

17 enrolled

Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT03246347 2026-01-23

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

40 enrolled 12 charts

Prostatic Neoplasms

NCT03456843 2026-01-21

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

190 enrolled

Stage IV Prostate Adenocarcinoma AJCC v7

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

53 enrolled 13 charts

Breast Neoplasms

NCT04872985 2026-01-06

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

140 enrolled

Breast Neoplasms

NCT04367311 2026-01-02

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

100 enrolled

Lung Neoplasms

NCT01154920 2025-12-17

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

128 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

32 enrolled

Prostatic Neoplasms

NCT04193059 2025-11-26

PANSY

1,560 enrolled

Breast Neoplasms

NCT03137771 2025-11-25

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

218 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT04386746 2025-11-17

GEMDOCE

27 enrolled 9 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

15 enrolled 17 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

NCT00295893 2025-09-25

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

121 enrolled 10 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT05252429 2025-09-12

Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma

27 enrolled

Head and Neck Neoplasms

NCT03340896 2025-09-02

SALTORL

256 enrolled

Squamous Cell Carcinoma of Head and Neck, Laryngeal Diseases

NCT04015622 2025-08-20

PROTRACT

100 enrolled

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT03421288 2025-07-25

DANTE

677 enrolled

Stomach Neoplasms

NCT04343885 2025-07-11

UpFrontPSMA

130 enrolled

Metastatic Hormone Naive Prostate Cancer

NCT03448835 2025-06-08

PANDA

20 enrolled

Stomach Neoplasms

NCT03951831 2025-04-25

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

26 enrolled

Neoplasms, Prostatic Neoplasms

NCT03161353 2025-04-23

PHERGain

377 enrolled

Breast Neoplasms

NCT02547987 2025-03-12

CADENCE

25 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05676203 2025-02-17

ARASAFE

250 enrolled

Prostatic Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT00798070 2024-12-18

PANTHER

2,017 enrolled

Breast Neoplasms, Neoplasms

NCT01957436 2024-11-12

PEACE1

1,173 enrolled

Neoplasms, Prostatic Neoplasms

NCT04723875 2024-11-01

Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline

Phase 2/3 Active not recruiting

306 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

136 enrolled

HER2-positive Breast Cancer

NCT03230734 2024-09-27

RAPSON

70 enrolled

Prostatic Neoplasms

NCT04158440 2024-07-09

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

501 enrolled